Biovitrum sells UK part

Biovitrum will soon spin-out a British subsidary

By Sophia Carlsson

January 22, 2009 12:00 AM

The Swedish biopharmaceutical

company Biovitrum has announced the initiation of a process aiming to spin out its small molecule UK based R&D subsidiary Cambridge Biotechnology, as well as a range of primary care projects.

According to Biovitrum,

this proposed transaction reflects its previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics. Biovitrum has engaged Nomura Code in this process.

The Cambridge Biotechnology

R&D pipeline includes one phase II neuropathic pain project; one phase II and one phase I obesity projects as well as a highly novel leptin mimetic candidate drug in obesity; and one pre-clinical and four pain and inflammation discovery programmes.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.